论文部分内容阅读
瑞格列奈 (repaglinide)是一种新型口服降糖药 ,是甲基甲胺苯甲酸 (CM BA)家族的一员。瑞格列奈于 1997年获美国FDA批准 ,并广泛应用于临床。为了解该药对 2型糖尿病患者血糖控制情况 ,笔者采用瑞格列奈单独用药、瑞格列奈与二甲双胍 ,瑞格列奈与拜糖平进行治疗观察 ,现将结果
Repaglinide is a new oral hypoglycemic agent that is part of the methylparaben (CM BA) family. Repaglinide was approved by the U.S. FDA in 1997 and is widely used clinically. In order to understand the type 2 diabetes patients with glycemic control of the drug, the author used repaglinide alone, repaglinide and metformin, repaglinide and cisplatin for treatment, the results will now